ReviewBiomolecules2019
Nanoparticle Activation Methods in Cancer Treatment.
Review in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Nanoparticle-based biomolecules in cancer diagnosis, therapy, drug delivery and prognosis.Frontiers in dental medicine · 2024Review
- Exploitation of High Tumour GSH Levels for Targeted siRNA Delivery in Rhabdomyosarcoma Cells.Biomolecules · 2022Article
- Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview.Nanotheranostics · 2022Review
- Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.International journal of nanomedicine · 2022Review
- Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques.International journal of nanomedicine · 2022Review
- Nanoparticles as Vectors to Tackle Cancer.Biomolecules · 2021Article
- Lipoic Acid-Modified Oligoethyleneimine-Mediated miR-34a Delivery to Achieve the Anti-Tumor Efficacy.Molecules (Basel, Switzerland) · 2021Article
- The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer.Journal of nanobiotechnology · 2021Article
- Importance of Nano Medicine and New Drug Therapies for Cancer.Advanced pharmaceutical bulletin · 2021Review
- Synergetic effects of thymoquinone-loaded porous PVPylated FeNanoscale advances · 2020Article
- Superparamagnetic Iron Oxide Nanoparticles Carrying Chemotherapeutics Improve Drug Efficacy in Monolayer and Spheroid Cell Culture by Enabling Active Accumulation.Nanomaterials (Basel, Switzerland) · 2020Article
- Biofunctionalization of Natural Fiber-Reinforced Biocomposites for Biomedical Applications.Biomolecules · 2020Review
- Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy.Frontiers in chemistry · 2020Review
- Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.Frontiers in immunology · 2020Review
- Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma.Nanomaterials (Basel, Switzerland) · 2019Review
- The Promise of Emergent Nanobiotechnologies for In Vivo Applications and Implications for Safety and Security.Health securityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we intend to highlight the progress which has been made in recent years around different types of smart activation nanosystems for cancer treatment. Conventional treatment methods, such as chemotherapy or radiotherapy, suffer from a lack of specific targeting and consequent off-target effects. This has led to the development of smart nanosystems which can effect specific regional and temporal activation. In this review, we will discuss the different methodologies which have been designed to permit activation at the tumour site. These can be divided into mechanisms which take advantage of the differences between healthy cells and cancer cells to trigger activation, and those which activate by a mechanism extrinsic to the cell or tumour environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.